Trautec Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 425

Employees

  • Latest Deal Type
  • IPO

  • Investors
  • 10

Trautec General Information

Description

Developer of recombinant collagen-based biomaterials designed for life and health new materials field. The company aims to develop recombinant human-derived collagen products, which can be applied in the fields of medicine, medical regeneration, and medical aesthetics, providing customers with innovative and high-quality products.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • No. 28 Shuanglong Road, Jintan Development Zone
  • Changzhou, Jiangsu 213212
  • China
+86 180
Primary Industry
Specialty Chemicals
Other Industries
Pharmaceuticals
Corporate Office
  • No. 28 Shuanglong Road, Jintan Development Zone
  • Changzhou, Jiangsu 213212
  • China
+86 180

Trautec Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trautec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. IPO 11-Nov-2024 Completed Profitable
6. Secondary Transaction - Private 18-Jun-2024 Completed Profitable
5. Later Stage VC (Series B) 18-Sep-2023 Completed Profitable
4. Later Stage VC (Series A) 16-Aug-2022 Completed Profitable
3. Secondary Transaction - Private 16-Aug-2022 Completed Profitable
2. Later Stage VC 30-Sep-2021 $4.94M $4.94M Completed Generating Revenue
1. Grant 01-Jan-2021 $76.4K Completed Generating Revenue
To view Trautec’s complete valuation and funding history, request access »

Trautec Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 1,276,600 $3.44 $3.44 1x $3.44 3.07%
To view Trautec’s complete cap table history, request access »

Trautec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of recombinant collagen-based biomaterials designed for life and health new materials field. The company aims
Specialty Chemicals
Changzhou, China
425 As of 2024

College Station, TX
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Trautec Competitors (2)

One of Trautec’s 2 competitors is Fujifilm Diosynth Biotechnologies, a Corporate Backed or Acquired company based in College Station, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fujifilm Diosynth Biotechnologies Corporate Backed or Acquired College Station, TX
Eluminex Biosciences Venture Capital-Backed Suzhou, China
You’re viewing 2 of 2 competitors. Get the full list »

Trautec Patents

Trautec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026145649-A1 Recombinant type iv collagen, and preparation method therefor and use thereof Pending 31-Dec-2024
WO-2026119282-A1 Recombinant type vii collagen having skin-whitening effect, preparation method therefor and use thereof Pending 05-Dec-2024
WO-2026108889-A1 Recombinant type i collagen and use thereof Pending 22-Nov-2024
WO-2025247065-A1 Preparation method for yeast-expressed type i recombinant human collagen with tri-helical structure and use thereof Pending 30-May-2024
WO-2025247066-A1 Preparation method for yeast-expressed type iii recombinant human collagen with tri-helical structure and use thereof Pending 30-May-2024 C12N15/815
To view Trautec’s complete patent history, request access »

Trautec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trautec Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
CLSA Capital Partners Asset Manager Minority
L Catterton PE/Buyout Minority
Mingfeng Capital PE/Buyout Minority
Shenzhen CDF Capital Venture Capital Minority
Boyu Capital Asset Manager Minority
You’re viewing 5 of 10 investors. Get the full list »

Trautec FAQs

  • When was Trautec founded?

    Trautec was founded in 2015.

  • Where is Trautec headquartered?

    Trautec is headquartered in Changzhou, China.

  • What is the size of Trautec?

    Trautec has 425 total employees.

  • What industry is Trautec in?

    Trautec’s primary industry is Specialty Chemicals.

  • Is Trautec a private or public company?

    Trautec is a Private company.

  • What is Trautec’s current revenue?

    The current revenue for Trautec is .

  • How much funding has Trautec raised over time?

    Trautec has raised $55M.

  • Who are Trautec’s investors?

    CLSA Capital Partners, L Catterton, Mingfeng Capital, Shenzhen CDF Capital, and Boyu Capital are 5 of 10 investors who have invested in Trautec.

  • Who are Trautec’s competitors?

    Fujifilm Diosynth Biotechnologies and Eluminex Biosciences are competitors of Trautec.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process